• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

活体肝移植或肝切除术联合术中射频消融治疗符合加利福尼亚大学旧金山分校 (UCSF) 标准的多灶性肿瘤 Child-Pugh A 期肝细胞癌患者。

Living donor liver transplantation or hepatic resection combined with intraoperative radiofrequency ablation for Child-Pugh A hepatocellular carcinoma patient with Multifocal Tumours Meeting the University of California San Francisco (UCSF) criteria.

机构信息

Department of Liver Surgery, Liver Transplantation Center, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China.

出版信息

J Cancer Res Clin Oncol. 2021 Feb;147(2):607-618. doi: 10.1007/s00432-020-03364-x. Epub 2020 Aug 27.

DOI:10.1007/s00432-020-03364-x
PMID:32852635
Abstract

BACKGROUND

How much difference there is between hepatic resection (HR) combined with intraoperative radiofrequency ablation (RFA) and living donor liver transplantation (LDLT) in treatment of multifocal hepatocellular carcinomas (HCCs) remains unclear. This study compared outcomes for patients with multifocal HCCs meeting the University of California San Francisco (UCSF) criteria treated by LDLT or HR + RFA.

METHODS

A total of 126 consecutive Child-Pugh A patients with multifocal HCCs meeting the UCSF criteria, who underwent LDLT (n = 51) or HR + RFA (n = 75), were included. Propensity score (PS) matching was performed to adjust for baseline differences. Overall survival (OS) and recurrence-free survival (RFS) were calculated, and subgroup, multivariate and nomogram analyses were performed.

RESULTS

LDLT provided significantly better OS and RFS than did HR + RFA before and after PS matching and reduced the dropout rate on waiting list, but HR + RFA was more convenient, less invasive and less cost. Patients with all lesions located in the same lobe had better OS and RFS than those located in the different lobes after HR + RFA. Multivariate and nomogram analyses revealed that HR + RFA, alpha-fetoprotein ≥ 400 ng/mL, the major tumour size > 3 cm and microvascular invasion were independent predictors of poor prognosis.

CONCLUSION

For Child-Pugh A patients with multiple HCCs meeting the UCSF criteria, LDLT may offer significantly better long-term results than did HR + RFA, and HR + RFA may still be considered as an acceptable curative therapy for those without considering transplantation or as a bridge treatment for a patient, with a plan for transplantation in the future.

摘要

背景

肝切除术(HR)联合术中射频消融(RFA)与活体肝移植(LDLT)治疗多灶性肝细胞癌(HCC)的疗效差异尚不清楚。本研究比较了符合加利福尼亚大学旧金山分校(UCSF)标准的多灶性 HCC 患者接受 LDLT 或 HR+RFA 治疗的结果。

方法

共纳入 126 例符合 UCSF 标准的 Child-Pugh A 级多灶性 HCC 患者,接受 LDLT(n=51)或 HR+RFA(n=75)治疗。采用倾向评分(PS)匹配来调整基线差异。计算总生存期(OS)和无复发生存期(RFS),并进行亚组、多变量和列线图分析。

结果

PS 匹配前后,LDLT 组的 OS 和 RFS 明显优于 HR+RFA 组,且降低了等待名单上的脱落率,但 HR+RFA 更方便、创伤更小、费用更低。HR+RFA 治疗后,所有肿瘤位于同一肝叶的患者 OS 和 RFS 优于肿瘤位于不同肝叶的患者。多变量和列线图分析显示,HR+RFA、甲胎蛋白(AFP)≥400ng/ml、肿瘤最大径>3cm 和微血管侵犯是预后不良的独立预测因素。

结论

对于符合 UCSF 标准的多灶性 HCC 且 Child-Pugh A 级的患者,LDLT 可能比 HR+RFA 提供更好的长期结果,对于不考虑移植或计划未来移植的患者,HR+RFA 仍可作为一种可接受的根治性治疗方法,或作为一种桥接治疗方法。

相似文献

1
Living donor liver transplantation or hepatic resection combined with intraoperative radiofrequency ablation for Child-Pugh A hepatocellular carcinoma patient with Multifocal Tumours Meeting the University of California San Francisco (UCSF) criteria.活体肝移植或肝切除术联合术中射频消融治疗符合加利福尼亚大学旧金山分校 (UCSF) 标准的多灶性肿瘤 Child-Pugh A 期肝细胞癌患者。
J Cancer Res Clin Oncol. 2021 Feb;147(2):607-618. doi: 10.1007/s00432-020-03364-x. Epub 2020 Aug 27.
2
Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma.射频(热)消融术与不干预或其他干预措施治疗肝细胞癌的比较
Cochrane Database Syst Rev. 2013 Dec 19;2013(12):CD003046. doi: 10.1002/14651858.CD003046.pub3.
3
Small masses (≤3 cm) diagnosed as hepatocellular carcinoma on pre-treatment imaging: comparison of therapeutic outcomes between hepatic resection and radiofrequency ablation.术前影像学诊断为≤3cm 的小肝癌:肝切除术与射频消融术治疗效果的比较。
Br J Radiol. 2020 Jan;93(1105):20190719. doi: 10.1259/bjr.20190719. Epub 2019 Nov 4.
4
Comparison of Hepatic Resection Combined with Intraoperative Radiofrequency Ablation, or Hepatic Resection Alone, for Hepatocellular Carcinoma Patients with Multifocal Tumors Meeting the University of California San Francisco (UCSF) Criteria: A Propensity Score-Matched Analysis.比较符合加利福尼亚大学旧金山分校(UCSF)标准的多灶性肝癌患者行肝切除术联合术中射频消融与单纯肝切除术的疗效:倾向评分匹配分析。
Ann Surg Oncol. 2020 Jul;27(7):2334-2345. doi: 10.1245/s10434-020-08231-0. Epub 2020 Feb 3.
5
Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma.射频消融与肝切除术治疗小肝细胞癌的荟萃分析。
BMC Gastroenterol. 2010 Jul 9;10:78. doi: 10.1186/1471-230X-10-78.
6
Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis.早期或极早期肝细胞癌患者的管理:一项网络荟萃分析尝试
Cochrane Database Syst Rev. 2017 Mar 28;3(3):CD011650. doi: 10.1002/14651858.CD011650.pub2.
7
[Comparison of the efficacy of anatomical resection versus hepatic parenchymal preservation preference in patients with solitary small hepatocellular carcinoma and cirrhosis: a multicenter retrospective study].[孤立性小肝细胞癌合并肝硬化患者解剖性切除与肝实质保留优先策略疗效比较:一项多中心回顾性研究]
Zhonghua Gan Zang Bing Za Zhi. 2025 Apr 20;33(4):348-358. doi: 10.3760/cma.j.cn501113-20250315-00097.
8
Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma.经皮乙醇注射或经皮乙酸注射治疗早期肝细胞癌。
Cochrane Database Syst Rev. 2015 Jan 26;1(1):CD006745. doi: 10.1002/14651858.CD006745.pub3.
9
Ablative and non-surgical therapies for early and very early hepatocellular carcinoma: a systematic review and network meta-analysis.早期和极早期肝细胞癌的消融和非手术治疗:系统评价和网络荟萃分析。
Health Technol Assess. 2023 Dec;27(29):1-172. doi: 10.3310/GK5221.
10
Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma.射频消融治疗肝细胞癌的生存和疾病复发的系统评价和荟萃分析。
Br J Surg. 2011 Sep;98(9):1210-24. doi: 10.1002/bjs.7669. Epub 2011 Jul 15.

引用本文的文献

1
Surgical treatment strategies for multifocal hepatocellular carcinomas.多灶性肝细胞癌的手术治疗策略
Hepatobiliary Surg Nutr. 2024 Dec 1;13(6):1071-1076. doi: 10.21037/hbsn-24-408. Epub 2024 Nov 20.
2
2023 Update of Indian National Association for Study of the Liver Consensus on Management of Intermediate and Advanced Hepatocellular Carcinoma: The Puri III Recommendations.印度国家肝脏研究协会关于中晚期肝细胞癌管理共识的2023年更新:普里III建议
J Clin Exp Hepatol. 2024 Jan-Feb;14(1):101269. doi: 10.1016/j.jceh.2023.08.005. Epub 2023 Aug 19.
3
Albumin-Globulin Score Combined with Skeletal Muscle Index as a Novel Prognostic Marker for Hepatocellular Carcinoma Patients Undergoing Liver Transplantation.

本文引用的文献

1
Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial.肝癌肿瘤降期后行肝移植的研究(XXL):一项随机、对照、2b/3 期临床试验。
Lancet Oncol. 2020 Jul;21(7):947-956. doi: 10.1016/S1470-2045(20)30224-2.
2
Combination of Resection and Ablative Treatment for Hepatocellular Carcinoma: Usefulness of Complementary Radiofrequency Ablation.肝肿瘤切除术联合消融治疗:补充射频消融的应用价值。
Oncology. 2019;96(5):242-251. doi: 10.1159/000496225. Epub 2019 Mar 20.
3
Increasing Liver Transplantation Wait-List Dropout for Hepatocellular Carcinoma With Widening Geographical Disparities: Implications for Organ Allocation.
白蛋白-球蛋白评分联合骨骼肌指数作为肝移植肝细胞癌患者的新型预后标志物
J Clin Med. 2023 Mar 14;12(6):2237. doi: 10.3390/jcm12062237.
4
Evaluation of 3D-CEUS in the Recurrence of Liver Cancer after Radiofrequency Ablation.射频消融术后肝癌复发的 3D-CEUS 评估。
J Healthc Eng. 2021 Dec 20;2021:3123553. doi: 10.1155/2021/3123553. eCollection 2021.
肝癌导致肝移植候补者不断退出,且地域差异不断扩大:对器官分配的影响。
Liver Transpl. 2018 Oct;24(10):1346-1356. doi: 10.1002/lt.25317.
4
Treatment Optimization for Hepatocellular Carcinoma in Elderly Patients in a Japanese Nationwide Cohort.日本全国队列中老年肝细胞癌患者的治疗优化。
Ann Surg. 2019 Jul;270(1):121-130. doi: 10.1097/SLA.0000000000002751.
5
[Diagnosis, management, and treatment of hepatocellular carcinoma (V2017)].肝细胞癌的诊断、管理与治疗(2017年版)
Zhonghua Gan Zang Bing Za Zhi. 2017 Dec 20;25(12):886-895. doi: 10.3760/cma.j.issn.1007-3418.2017.12.002.
6
Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma Using Quantitative Image Analysis.使用定量图像分析对肝细胞癌微血管侵犯进行术前预测
J Am Coll Surg. 2017 Dec;225(6):778-788.e1. doi: 10.1016/j.jamcollsurg.2017.09.003. Epub 2017 Sep 21.
7
Global trends and predictions in hepatocellular carcinoma mortality.全球肝癌死亡率的趋势和预测。
J Hepatol. 2017 Aug;67(2):302-309. doi: 10.1016/j.jhep.2017.03.011. Epub 2017 Mar 21.
8
Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma.基于证据的肝细胞癌患者诊断、分期和治疗。
Gastroenterology. 2016 Apr;150(4):835-53. doi: 10.1053/j.gastro.2015.12.041. Epub 2016 Jan 12.
9
Multiple Tumors Located in the Same Section Are Associated with Better Outcomes After Hepatic Resection for HCC Patients Meeting the Milan Criteria.对于符合米兰标准的肝癌患者,同一肝段内的多个肿瘤与肝切除术后更好的预后相关。
J Gastrointest Surg. 2015 Dec;19(12):2207-14. doi: 10.1007/s11605-015-2959-0. Epub 2015 Sep 22.
10
Hepatectomy, combined with intraoperative radiofrequency ablation in patients with multiple hepatocellular carcinomas.肝切除术联合术中射频消融治疗多发性肝细胞癌患者。
Korean J Hepatobiliary Pancreat Surg. 2015 Aug;19(3):98-102. doi: 10.14701/kjhbps.2015.19.3.98. Epub 2015 Aug 28.